2024-11-19 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Abbott Laboratories (ABT), a global healthcare company that develops, manufactures, and markets a broad range of health care products, including medical devices, diagnostics, branded generic medicines, and nutritional products, has underperformed the S&P 500 (VOO) over the given period.  The cumulative return for ABT is 96.37%, while the VOO's cumulative return is 124.78%. This represents a difference of -28.41%.  The relative divergence of -28.41% sits at the 13.53 percentile of historical divergence between ABT and VOO, indicating it's relatively close to the lower end of the historical range of underperformance.  While the alpha shows periods of outperformance,  recent years reveal a beta consistently below 1 and declining, suggesting less sensitivity to overall market movements than in previous years.


**2. Recent Price Movement:**

* **Closing Price:** $117.36 (Last Market: $117.38)
* **5-Day Moving Average:** $116.09
* **20-Day Moving Average:** $115.96
* **60-Day Moving Average:** $114.93

The price is slightly above the short-term moving averages, suggesting some upward momentum, but still below the longer-term 60-day average.


**3. Technical Indicators and Expected Return:**

* **RSI:** 62.06 (Slightly above the neutral level of 50, indicating neither overbought nor oversold conditions)
* **PPO:** -0.06 (Negative value suggests bearish momentum)
* **20-Day Relative Divergence Change:** -0.75 (Indicates a recent short-term downward trend)
* **Expected Return:** 0.0% (This indicates that the expected long-term (2+ years) return, assuming continued investment, is currently projected to be equivalent to the S&P 500.  Given the historical data, however, this projection should be considered with caution).  The current price ($117.38) is not significantly different enough to signal a dramatic price movement (no significant spike or drop is observed).

**4. Recent Financial Performance and Outlook:**

The provided EPS and revenue data show relatively stable performance with slight fluctuations.  There is no information provided to judge whether the 2024-10-31 results meet or exceed market expectations. Further analysis with the earnings release and analyst reports is required for a thorough evaluation.

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-10-31 | 0.94 | $10.63B       |
| 2024-07-31 | 0.74 | $10.38B       |
| 2024-05-02 | 0.70 | $9.96B        |
| 2023-11-01 | 0.82 | $10.14B       |
| 2024-10-31 | 0.82 | $10.14B (duplicate entry - likely a data entry error) |


**5. Revenue and Profitability:** (This section is part of 6 and integrated below for better flow)

**6. Financial Information Analysis:**

The provided financial data shows relatively stable revenue and high profit margins.  The Return on Equity (ROE) fluctuates but generally stays positive, indicating profitable use of shareholder equity.  There is a notable dip in both ROE and profit margins in Q1 of 2024, however. The long-term trend needs further examination with more financial reporting to ascertain if this is a trend or just a quarterly fluctuation.

| Quarter     | Revenue     | Profit Margin | Equity  | ROE    |
|-------------|-------------|----------------|---------|--------|
| 2024-09-30  | $10.63B     | 55.83%         | $39.80B | 4.14%  |
| 2024-06-30  | $10.38B     | 55.64%         | $39.32B | 3.31%  |
| 2024-03-31  | $9.96B      | 55.21%         | $38.81B | 3.16%  |
| 2023-12-31  | $10.24B     | 55.51%         | $38.60B | 4.13%  |
| 2023-09-30  | $10.14B     | 54.60%         | $37.48B | 3.83%  |


**7. News and Recent Issues:**

* **Information Required:** To provide a complete analysis of recent news and market outlook, please provide links or text from recent articles (within the last two days) from sources like Shacknews and Finbold, focusing on ABT's earnings and analyst opinions.  Without this information, I cannot provide specific details on recent market sentiment or analyst highlights.

**8. Overall Analysis Summary:**

Abbott Laboratories (ABT) demonstrates a history of strong revenue and profitability, though recent quarterly data shows some decline.  While it has historically shown periods of outperformance relative to the S&P 500 (as indicated by positive alpha values), recent performance has lagged the broader market.  Technical indicators paint a mixed picture, with the RSI suggesting a neutral stance and the PPO indicating bearish momentum. The recent short-term decline is also shown in the relative divergence.  Further analysis is necessary to fully determine the causes behind this short-term decline and to better predict future performance. The addition of current news and analyst opinions is crucial for a more comprehensive evaluation.

**9.  Disclaimer:** This analysis is based on the limited data provided. It is not financial advice and should not be used as the sole basis for investment decisions.  Conduct thorough independent research and consult with a financial advisor before making any investment choices.
